TSHA - Taysha Gene Therapies Inc. (TSHA) Q1 2024 Earnings Call Transcript
2024-05-15 04:55:23 ET
Taysha Gene Therapies, Inc. (TSHA)
Q1 2024 Earnings Conference Call
May 14, 2024, 4:30 PM ET
Company Participants
Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations
Sean Nolan - Chief Executive Officer and Chairman
Sukumar Nagendran - President and Head of Research and Development
Kamran Alam - Chief Financial Officer
Conference Call Participants
Kristen Kluska - Cantor Fitzgerald
Salveen Richter - Goldman Sachs
Whitney Ijem - Canaccord Genuity
Joon Lee - Truist Securities
Maury Raycroft - Jefferies
Christopher Raymond - Piper Sandler
Gil Blum - Needham and Company
Yanan Zhu - Wells Fargo
Jack Allen - Baird
Silvan Tuerkcan - JMP Securities
Presentation
Operator
Greetings and welcome to the Taysha Gene Therapies First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Hayleigh Collins. Thank you. You may begin.
Hayleigh Collins
Thank you. Good afternoon and welcome to Taysha's First Quarter 2024 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the first quarter ended March 31st, 2024.
A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's CEO; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer.
We will hold a question-and-answer session following our prepared remarks. Please note that on today's call, we will be making forward-looking statements including statements relating to the therapeutic and commercial potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in our first and second patient dosed in the REVEAL trial to positively impact quality of life and the course of disease in the patients we seek to treat our research, development and regulatory plans for our product candidates, including the timeline for our clinical trials and reporting results therefrom, in our current cash resources supporting our planned operating expenses and capital requirements into 2026.
These statements may include the expected timing and results of clinical trials for our product candidates and other clinical and regulatory plans, and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway and future operating results, discovery and development of product candidates, strategic alliances and intellectual property as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements....
Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript